Rishi Puri

Rishi Puri

Auto-generated profile, based on publicly available information

Rishi Puri

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
PMPreethi Mani
Preethi Mani
RPRishi Puri
Rishi Puri
GSGregory G. Schwartz
Gregory G. Schwartz
SNSteven E. Nissen
Steven E. Nissen
MSMingyuan Shao
Mingyuan Shao
SNStephen Nicholls
Stephen Nicholls
Residual risk of ischemic cardiovascular events or death remains high following an acute coronary syndrome (ACS) despite optimal guideline-directed coronary revascularization and treatment with antiplatelet and low-density lipoprotein cholesterol lowering agents.1,2 Identifying biomarkers associated with this residual risk may help guide interventions targeted to lower these levels.

1 October 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
RPRishi Puri
Rishi Puri
SNSteven E. Nissen
Steven E. Nissen
BABenoit J. Arsenault
Benoit J. Arsenault
JJJulie St John
Julie St John
JRJeffrey S. Riesmeyer
Jeffrey S. Riesmeyer
SNStephen J. Nicholls
Stephen J. Nicholls
Lipoprotein(a) (Lp[a]) levels are genetically mediated and considered to be causal in the development of atherosclerotic cardiovascular disease (ASCVD).1,2 Although reducing low-density lipoprotein cholesterol levels remains the dominant means of attenuating ASCVD risk, substantial residual risk despite established therapies has led to the effort to identify novel biomarkers and treatment targets.3 Lipoprotein(a) has thus emerged as a potential therapeutic target, with antisense oligonucleotides directed specifically at hepatocytes demonstrating substantial 70% to 90% reductions in circulating Lp(a) levels in early-phase clinical trials in humans.4 Despite these recent advances, it remains unclear which patient populations would benefit the most from Lp(a) reduction, and what degree of Lp(a) lowering would be required to demonstrate incremental clinical benefit despite the use of background established medical therapies.5,6

1 November 2018 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
JAJordan Andrews
Jordan Andrews
PPPeter J. Psaltis
Peter J. Psaltis
BBBelinda Di Bartolo
Belinda Di Bartolo
SNStephen Nicholls
Stephen Nicholls
RPRishi Puri
Rishi Puri

21 April 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DCDonald Clark
Donald Clark
SNStephen J Nicholls
Stephen J Nicholls
JJJulie St. John
Julie St. John
MEMohamed B Elshazly
Mohamed B Elshazly
SKSamir R Kapadia
Samir R Kapadia
RPRishi Puri
Rishi Puri
Utilizing serial intravascular ultrasonography (IVUS), we aimed to exam the association of intra-individual lipid variability, coronary atheroma progression, and clinical outcomes. We performed a post hoc patient-level analysis of nine clinical trials involving 4976 patients with coronary artery disease who underwent serial coronary IVUS in the setting of a range of medical therapies. We assessed the associations between progression in percent atheroma volume (ΔPAV), clinical outcomes, and visit-to-visit lipid variability including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC)/HDL-C, and apolipoprotein B (ApoB). Variability of lipid parameters was measured using intra-individual standard deviation over 3, 6, 12, 18, and 24 months. Atherogenic lipoprotein variability significantly associated with ΔPAV [odds ratio (95% confidence interval; P-value), LDL-C: 1.09 (1.02, 1.17, P = 0.01); non-HDL-C: 1.10 (1.02, 1.18, P = 0.01); TC/HDL-C: 1.14 (1.06, 1.24, P = 0.001); ApoB: 1.13 (1.03, 1.24, P = 0.01)]. Survival curves revealed significant stepwise relationships between cumulative major adverse cardiovascular events and increasing quartiles of atherogenic lipoprotein variability at 24-months follow-up (log-rank P < 0.01 for all lipoproteins except HDL-C). Stronger associations were noted between achieved lipoprotein levels and ΔPAV [LDL-C: 1.27 (1.17, 1.39; P < 0.001); non-HDL-C: 1.32 (1.21, 1.45; P < 0.001); TC/HDL-C: 1.31 (1.19, 1.45; P < 0.001); ApoB: 1.20 (1.07, 1.35; P = 0.003)]. Greater visit-to-visit variability in atherogenic lipoprotein levels significantly associates with coronary atheroma progression and clinical outcomes, although the association between achieved atherogenic lipoproteins and atheroma progression appears stronger. These data highlight the importance of achieving low and consistent atherogenic lipoprotein levels to promote plaque regression and improve clinical outcomes.

1 April 2021 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
RTRayji S. Tsutsui
Rayji S. Tsutsui
YSYasser Sammour
Yasser Sammour
AKAnkur Kalra
Ankur Kalra
GRGrant Reed
Grant Reed
AKAmar Krishnaswamy
Amar Krishnaswamy
RPRishi Puri
Rishi Puri

1 September 2018 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
JAJordan Andrews
Jordan Andrews
PPPeter J. Psaltis
Peter J. Psaltis
OBOzgur Bayturan
Ozgur Bayturan
MSMingyuan Shao
Mingyuan Shao
BSBrian Stegman
Brian Stegman
RPRishi Puri
Rishi Puri